Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose, sequentially designed, single-period study to determine
the effect of moderate renal impairment on the pharmacokinetics (PK) of CTP-543 and its major
metabolites following administration of a single 12 mg oral dose of CTP-543.